Related Experiment Video

Updated: Sep 7, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway

Maaza G-Amlak1, Shahab Uddin, Dolores Mahmud

  • 1Hematology/Oncology Section, University of Illinois Medical Center and West Side VA Medical Center, Chicago, IL 60607, USA.

Biochemical and Biophysical Research Communications
|October 3, 2002
PubMed

Insights

Interleukin-6 (IL-6) promotes myeloma cell growth via the PI3/Akt pathway. Inhibiting glycogen synthase kinase 3 (Gsk3) blocks IL-6 effects, suppressing growth and inducing apoptosis in myeloma cells.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cell Signaling

Background:

  • Interleukin-6 (IL-6) signaling is crucial for myeloma cell proliferation and survival.
  • The PI3/Akt kinase pathway is a key mediator of IL-6's effects in myeloma.
  • Understanding downstream signaling is vital for targeting myeloma growth.

Purpose of the Study:

  • To investigate the roles of glycogen synthase kinase 3 (Gsk3) and forkhead transcription factors (FH) in IL-6-mediated myeloma cell growth.
  • To elucidate the downstream signaling mechanisms within the PI3/Akt pathway regulating myeloma progression.

Main Methods:

  • Utilized the RPMI-8226 myeloma cell line.
  • Analyzed the phosphorylation status of Gsk3 and FH transcription factors (FKHRL1, FKHR, AFX) in response to IL-6.
  • Assessed the effects of Gsk3 inhibitors on FKHRL1/FKHR dephosphorylation, p27(kip1) levels, cell growth, and apoptosis.

Main Results:

  • IL-6 was found to phosphorylate and inactivate Gsk3 and FH transcription factors FKHRL1, FKHR, and AFX.
  • Gsk3 inhibition led to dephosphorylation of FKHRL1 and FKHR, and increased levels of p27(kip1).
  • Inhibition of Gsk3 activity effectively suppressed myeloma cell growth and induced apoptosis, overriding IL-6 signaling.

Conclusions:

  • Gsk3 and FH transcription factors are critical downstream effectors of IL-6 signaling in myeloma.
  • Targeting Gsk3 represents a potential therapeutic strategy to overcome IL-6-driven myeloma cell growth and survival.
  • Pharmacological inhibition of Gsk3 can induce myeloma cell death, offering a novel approach for treatment.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...